amrinone has been researched along with Cardiac Failure in 192 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the hemodynamic effects of amrinone and dobutamine in patients 75 years of age or older who have severe congestive heart failure requiring invasive hemodynamic monitoring and inotropic support." | 9.08 | A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. ( Barbarash, R; Beckham, V; Coulter, L; Davila-Roman, VG; Kurz, H; Morello, PJ; Rich, MW; Sperry, J; Spinner, L; Woods, WL, 1995) |
| "We report the results of a multicenter study performed on 70 patients with severe congestive heart failure of different etiology (ischemic, idiopathic, alcoholic, valvular and secondary to antiblastic drugs) to evaluate the clinical and hemodynamic effects and tolerability of low dose amrinone iv (0." | 9.07 | [Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure]. ( Dei Cas, L; Metra, M; Nodari, S; Raddino, R; Visioli, O, 1991) |
| "Hemodynamic measurements were done in 42 patients with congestive heart failure of NYHA classes III and IV after administration of the phosphodiesterase inhibitors amrinone und enoximone." | 9.07 | [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]. ( Peters, P; Saborowski, F; Schneider, M, 1991) |
| "A prospective randomized study was performed in 46 consecutive patients with refractory congestive heart failure (CHF) due to idiopathic dilated cardiomyopathy to compare the hemodynamic responses to 48-hour infusions of amrinone and dobutamine." | 9.06 | Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. ( Marcus, RH; Mitha, A; Patel, J; Raw, K; Sareli, P, 1990) |
| "To verify favourable long-term effects, 14 patients with chronic congestive heart failure, NYHA class II-IV, who had been treated with oral amrinone for 8-15 months with apparent clinical benefit, had the drug withdrawn according to a 12 week placebo controlled double-blind crossover protocol." | 9.06 | Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial. ( Bette, L; Fröhlig, G; Rettig, G; Schieffer, H; Sen, S, 1986) |
| "Eighteen patients with congestive heart failure were studied in a double-blind, randomized, placebo-controlled withdrawal trial to evaluate the effectiveness of chronic oral amrinone therapy when added to conventional heart failure therapy." | 9.05 | Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. ( Bashore, TM; Evans, JR; Huss, P; Leier, CV; Pacht, K; Unverferth, DV, 1984) |
| "A placebo-controlled study was employed to evaluate the effects of oral amrinone in patients with congestive heart failure." | 9.05 | Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. ( Benotti, JR; DiBianco, R; Leier, CV; Shabetai, R; Silverman, BD, 1984) |
| "Amrinone, 100 mg orally every 8 hours, was administered to 13 patients with moderate-to-severe congestive heart failure (CHF) for 1 month on an outpatient basis to determine the beneficial and undesirable effects of this new cardioactive agent in this clinical setting." | 9.05 | Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. ( Bashore, TM; Dalpiaz, K; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure." | 9.05 | Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. ( Bourassa, M; DiBianco, R; Hess, M; Konstam, M; Likoff, M; Massie, B; Packer, M, 1985) |
| "Hemodynamic dose-response effects of intravenous amrinone were studied in 22 male patients aged 38 to 62 years with left ventricular failure occurring within 18 hours of acute myocardial infarction." | 9.05 | Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. ( Hafizullah, M; Hussain, M; Jackson, NC; Reynolds, G; Richmond, A; Silke, B; Taylor, SH; Verma, SP, 1985) |
| " Milrinone, which is structurally similar to amrinone, is an oral agent under investigation for the treatment of congestive heart failure." | 8.77 | Milrinone, a new agent for the treatment of congestive heart failure. ( Hasegawa, GR, 1986) |
| "We investigated the hemodynamic effects of amrinone and assessed its effects on neurohormonal factors in 15 patients with evolving congestive heart failure with various origins." | 7.70 | Hemodynamic effect of amrinone depends on pretreatment vascular resistance in patients with evolving congestive heart failure: correlation between vascular resistance and neurohormonal activity. ( Baba, T; Komamura, K; Miyatake, K; Noguchi, T; Ohmori, F; Sasaki, T; Tomimoto, S, 1998) |
| "We report two cases in which amrinone was used effectively, in addition to the conventional sympathomimetic drug, for the emergence from cardiopulmonary bypass following complicated valvular heart surgery in patients who had severe pulmonary hypertension and biventricular failure." | 7.68 | Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery. ( Asokumar, B; Cheng, DC; Nakagawa, T, 1993) |
| "To describe the experience of 41 New York Heart Association (NYHA) class III and IV heart failure patients treated with intermittent intravenous amrinone infusions in addition to conventional therapy." | 7.68 | Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure. ( Levinoff Roth, SN; Moe, G, 1993) |
| "The use of amrinone, a cardiac inotropic agent with vasodilatory properties, has not been described in human pregnancy." | 7.68 | Use of intravenous amrinone in the short-term management of refractory heart failure in pregnancy. ( Bhatia, RK; Ganguly, S; Jelsema, RD, 1991) |
| "The hemodynamic response to amrinone was analyzed in 19 patients with severe heart failure (NYHA III or IV)." | 7.68 | [The hemodynamic profile of the response to amrinone treatment in severe heart failure]. ( Altimiras Ruiz, J; Bayés de Luna, A; Binia Mizrahi, M; Domínguez de Rozas, J; García Picart, J; Guindo Soldevila, J; Pastor Ramón, E, 1991) |
| "The incidence of amrinone-induced thrombocytopenia has been reported to be 2." | 7.68 | Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. ( Burnette, PK; Manny, RP; Mattingly, PM; Weston, MW, 1990) |
| "Short-term amrinone therapy has been shown to exert beneficial hemodynamic effects in patients with heart failure." | 7.67 | Amrinone therapy in patients with heart failure. Lack of improvement in functional capacity and left ventricular function at rest and during exercise. ( Humen, DP; Johnston, DL; Kostuk, WJ, 1984) |
| "To determine the hemodynamic and clinical effects of long-term positive inotropic stimulation on the myocardium, we treated 31 patients with severe chronic heart failure with oral amrinone (600 mg daily) and performed invasive hemodynamic studies during short- and long-term treatment with the drug." | 7.67 | Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Although amrinone produces acute hemodynamic improvement in patients with severe chronic congestive heart failure (CHF), it has not produced clinical benefits in long-term controlled trials." | 7.67 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Seven patients with severe congestive heart failure received amrinone i." | 7.67 | Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. ( Hermiller, JB; Leier, CV; Leithe, ME; Magorien, RD; Unverferth, DV, 1984) |
| "The efficacy and safety of oral amrinone were examined in 17 patients with moderately severe to severe heart failure that was refractory to standard medical therapy and vasodilators." | 7.67 | Amrinone in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Sutton, MS; Weber, KT; Wilson, H, 1984) |
| "The frequency and characteristics of thrombocytopenia resulting from administration of amrinone, a new inotropic and vasodilator agent, was evaluated in 43 patients." | 7.67 | Amrinone-induced thrombocytopenia. ( Ansell, J; Benotti, JR; McCue, J; Parrilla, N; Tiarks, C, 1984) |
| "In a prospective trial, the immediate and long-term haematological effects of amrinone were studied in sixteen patients with refractory cardiac failure." | 7.67 | The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. ( Al-Hasani, SF; Hamblin, AS; Kioy, PG; Lucas, GF; Savidge, GF; Semple, MJ; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "The effects of intravenous amrinone and sodium nitroprusside on haemodynamic indices, left ventricular contractility, and myocardial metabolism were compared in patients with cardiac failure." | 7.67 | Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. ( Coltart, DJ; Jenkins, BS; Juul, SM; Thompson, DS; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "The purpose of this study was to evaluate the effect of amrinone on the survival of a group of 51 Class IV congestive heart failure patients as well as changes in exercise capacity, hemodynamics, and clinical status." | 7.67 | Long term survival of class IV heart failure patients treated with oral amrinone. ( Moran, JF; Rad, N; Scanlon, PJ, 1989) |
| "The relative contribution of inotropic and vasodilator effect to amrinone-induced hemodynamic improvement in congestive heart failure (CHF) is unknown." | 7.67 | Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. ( Cohen, SR; Das, D; Isner, JM; Konstam, MA; Martin, TT; Salem, DN; Weiland, DS, 1986) |
| "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption." | 7.67 | Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985) |
| "The hemodynamic and hormonal responses to dobutamine alone and with the addition of amrinone were studied in ten patients with severe heart failure." | 7.67 | Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. ( Kolesar, JA; Lawless, CE; Reddy, PS; Uretsky, BF; Valdes, AM; Verbalis, JG, 1987) |
| "To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously." | 7.67 | Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The pharmacokinetics of amrinone and its relationship to ventricular function were assessed in 15 patients with chronic cardiac failure following the administration of a single 100 mg oral dose." | 7.67 | Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ( Andrews, V; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1987) |
| "The effects of amrinone, dobutamine, and a combination of the two drugs on peak positive left ventricular dP/dt and left ventricular performance were evaluated in 11 patients with chronic congestive heart failure." | 7.67 | Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. ( Gage, J; LeJemtel, TH; Lucido, D; Rutman, H, 1986) |
| "To determine the factors conditioning the variability of positive inotropic response after intravenous acute amrinone administration, 14 patients with chronic cardiac failure were studied by quantitative M-mode and cross-sectional echocardiography." | 7.67 | Variability of positive inotropic response to acute amrinone administration in chronic cardiac failure. ( Cargnelli, G; Dalla-Volta, S; Fasoli, G; Maragno, I; Piovan, D; Scognamiglio, R; Visintin, L, 1986) |
| "The hemodynamic effects of a newly developed inotropic agent, amrinone (AMN) were studied and compared with those of dopamine (DA) and dobutamine (DB) in forty patients with pump failure due to acute myocardial infarction." | 7.67 | Effects of intravenous amrinone on heart failure complicated by acute myocardial infarction: comparative study with dopamine and dobutamine. ( Seino, Y; Takano, T; Tanaka, K, 1986) |
| "Amrinone, a new inotropic agent, was used to treat 24 patients with chronic congestive heart failure who were classified as clinically stable and who were in New York Heart Association's classes II and III." | 7.67 | Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure. ( Gerber, L; Merrill, AJ; Silverman, BD, 1985) |
| "Amrinone, a positive inotropic-vasodilator agent, was administered to anaesthetised dogs in an attempt to reverse heart failure induced by drugs possessing negative inotropic properties." | 7.67 | The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog. ( Alousi, AA; Canter, JM; Fort, DJ, 1985) |
| "Seven patients with severe congestive heart failure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72)." | 7.66 | Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure. ( Forman, R; Frishman, W; LeJemtel, TH; Maskin, C; Ribner, H; Siegel, LA; Sonnenblick, EH; Strom, J; Wexler, J, 1983) |
| "A patient with severe cardiac failure due to idiopathic congestive cardiomyopathy resistant to conventional therapy, responded to amrinone, a new non-glycosidic non-catecholamine positive inotropic agent." | 7.66 | Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure. ( Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981) |
| "Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks)." | 7.66 | Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. ( Forman, R; Klein, NA; LeJemtel, TH; Maskin, CS; Sonnenblick, EH, 1982) |
| "To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27." | 7.66 | Clinical experience with amrinone in patients with advanced congestive heart failure. ( Ballard, JO; Burks, JM; Carlin, B; Hallahan, WF; Kinney, EL; Zelis, R, 1982) |
| "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure." | 7.66 | Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. ( Frishman, WH; Klein, NA; LeJemtel, TH; Siskind, SJ; Sonnenblick, EH, 1981) |
| "The acute effects of an oral preparation of amrinone, a recently synthesized cardiotonic agent, were assessed noninvasively in nine patients who had advanced heart failure that persisted despite treatment with digitalis, diuretic drugs and afterload-reducing agents." | 7.66 | Oral amrinone in refractory congestive heart failure. ( Benotti, JR; Braunwald, E; Curfman, GD; Grossman, W; Holman, BL; Malacoff, RF; Smith, TW; Wynne, J, 1980) |
| "Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown." | 7.66 | Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. ( Benotti, JR; Braunwald, E; Carabello, BA; Grossman, W, 1980) |
| "Eight patients with congestive heart failure and 10 age- and sex-matched healthy volunteers were studied." | 6.69 | Impaired vasodilatation response to amrinone in the forearm of patients with congestive heart failure: role of endothelium-derived nitric oxide. ( Hirano, Y; Inoue, SI; Ishibashi, Y; Murakami, Y; Nakamura, K; Ohata, S; Sakane, T; Shimada, T; Sugamori, T; Takahashi, N, 2000) |
| "Amrinone is a new positive inotropic agent available in oral and intravenous preparations." | 6.66 | [Effects of amrinone administered orally and by injection in heart failure]. ( Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 6.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "A 55-year-old man developed acute respiratory failure, pulmonary hypertension and left heart failure due to acute myocardial infarction." | 5.30 | Concurrent administration of amrinone with nitric oxide most improves PaO2/FiO2 in acute respiratory and cardiac failure. ( Fujimori, M; Hayashi, M; Yamada, T; Yukioka, H, 1999) |
| "The prevalence of congestive heart failure (CHF) and its progressive degenerative course continue to generate pressure for alternative, more effective means of treatment." | 5.28 | Home intermittent amrinone infusions in terminal congestive heart failure. ( Baptista, RJ; Mitrano, FP; Perri-LaFrancesca, J, 1989) |
| "Amrinone is an effective inotropic agent, but its electrophysiologic effects in humans have not been previously determined." | 5.27 | Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. ( Dougherty, AH; Goldstein, RA; Gray, EL; Hanna, JE; Naccarelli, GV, 1984) |
| " Catecholamine dosage was held constant during the period of the study." | 5.27 | Effect of amrinone in acute severe cardiac failure. ( Frenking, B; Gülker, H; Heuer, H, 1988) |
| "To compare the hemodynamic effects of amrinone and dobutamine in patients 75 years of age or older who have severe congestive heart failure requiring invasive hemodynamic monitoring and inotropic support." | 5.08 | A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. ( Barbarash, R; Beckham, V; Coulter, L; Davila-Roman, VG; Kurz, H; Morello, PJ; Rich, MW; Sperry, J; Spinner, L; Woods, WL, 1995) |
| "We report the results of a multicenter study performed on 70 patients with severe congestive heart failure of different etiology (ischemic, idiopathic, alcoholic, valvular and secondary to antiblastic drugs) to evaluate the clinical and hemodynamic effects and tolerability of low dose amrinone iv (0." | 5.07 | [Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure]. ( Dei Cas, L; Metra, M; Nodari, S; Raddino, R; Visioli, O, 1991) |
| "Hemodynamic measurements were done in 42 patients with congestive heart failure of NYHA classes III and IV after administration of the phosphodiesterase inhibitors amrinone und enoximone." | 5.07 | [The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]. ( Peters, P; Saborowski, F; Schneider, M, 1991) |
| "A prospective randomized study was performed in 46 consecutive patients with refractory congestive heart failure (CHF) due to idiopathic dilated cardiomyopathy to compare the hemodynamic responses to 48-hour infusions of amrinone and dobutamine." | 5.06 | Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. ( Marcus, RH; Mitha, A; Patel, J; Raw, K; Sareli, P, 1990) |
| "To verify favourable long-term effects, 14 patients with chronic congestive heart failure, NYHA class II-IV, who had been treated with oral amrinone for 8-15 months with apparent clinical benefit, had the drug withdrawn according to a 12 week placebo controlled double-blind crossover protocol." | 5.06 | Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial. ( Bette, L; Fröhlig, G; Rettig, G; Schieffer, H; Sen, S, 1986) |
| "Eighteen patients with congestive heart failure were studied in a double-blind, randomized, placebo-controlled withdrawal trial to evaluate the effectiveness of chronic oral amrinone therapy when added to conventional heart failure therapy." | 5.05 | Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. ( Bashore, TM; Evans, JR; Huss, P; Leier, CV; Pacht, K; Unverferth, DV, 1984) |
| "A placebo-controlled study was employed to evaluate the effects of oral amrinone in patients with congestive heart failure." | 5.05 | Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. ( Benotti, JR; DiBianco, R; Leier, CV; Shabetai, R; Silverman, BD, 1984) |
| "Amrinone, 100 mg orally every 8 hours, was administered to 13 patients with moderate-to-severe congestive heart failure (CHF) for 1 month on an outpatient basis to determine the beneficial and undesirable effects of this new cardioactive agent in this clinical setting." | 5.05 | Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. ( Bashore, TM; Dalpiaz, K; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "A number of uncontrolled studies have indicated that oral administration of amrinone, a phosphodiesterase inhibitor with potent positive inotropic effects in experimental preparations, may be beneficial in patients with chronic congestive heart failure." | 5.05 | Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. ( Bourassa, M; DiBianco, R; Hess, M; Konstam, M; Likoff, M; Massie, B; Packer, M, 1985) |
| "Clinical trials of intravenous amrinone were performed in 462 patients severely ill with congestive heart failure." | 5.05 | Clinical safety of intravenous amrinone--a review. ( Treadway, G, 1985) |
| "Hemodynamic dose-response effects of intravenous amrinone were studied in 22 male patients aged 38 to 62 years with left ventricular failure occurring within 18 hours of acute myocardial infarction." | 5.05 | Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction. ( Hafizullah, M; Hussain, M; Jackson, NC; Reynolds, G; Richmond, A; Silke, B; Taylor, SH; Verma, SP, 1985) |
| " Milrinone, which is structurally similar to amrinone, is an oral agent under investigation for the treatment of congestive heart failure." | 4.77 | Milrinone, a new agent for the treatment of congestive heart failure. ( Hasegawa, GR, 1986) |
| "We investigated the hemodynamic effects of amrinone and assessed its effects on neurohormonal factors in 15 patients with evolving congestive heart failure with various origins." | 3.70 | Hemodynamic effect of amrinone depends on pretreatment vascular resistance in patients with evolving congestive heart failure: correlation between vascular resistance and neurohormonal activity. ( Baba, T; Komamura, K; Miyatake, K; Noguchi, T; Ohmori, F; Sasaki, T; Tomimoto, S, 1998) |
| " Amrinone was administered to improve the features of congestive heart failure induced by retention of body fluid." | 3.70 | [General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy]. ( Kinoshita, T; Matsuda, T; Shigemi, K; Shimosato, G; Tanaka, Y, 1999) |
| "The present study compared the effects of amrinone, dobutamine, dibutyryl cAMP, digoxin, and isoproterenol on mechanical performance, the high energy phosphate metabolites, and the [Ca2+]i transients in normal and cardiomyopathic hamster hearts with severe heart failure." | 3.69 | Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts. ( Buser, PT; Jasmin, G; Parmley, WW; Wikman-Coffelt, J; Wu, SY, 1995) |
| "We report two cases in which amrinone was used effectively, in addition to the conventional sympathomimetic drug, for the emergence from cardiopulmonary bypass following complicated valvular heart surgery in patients who had severe pulmonary hypertension and biventricular failure." | 3.68 | Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery. ( Asokumar, B; Cheng, DC; Nakagawa, T, 1993) |
| "To describe the experience of 41 New York Heart Association (NYHA) class III and IV heart failure patients treated with intermittent intravenous amrinone infusions in addition to conventional therapy." | 3.68 | Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure. ( Levinoff Roth, SN; Moe, G, 1993) |
| "The authors describe the results obtained treating with amrinone for 48 hours 11 patients with acute heart failure." | 3.68 | [Efficacy and safety of amrinone in the treatment of heart insufficiency in intensive care]. ( Agrò, C; Costa, P; Gulotta, G; Papa, G; Piazza, F; Ronga, F; Sansone, A; Sparacia, B, 1992) |
| "The vasodilatory response to local specific type III phosphodiesterase inhibition with amrinone was evaluated before and immediately after local administration of digoxin in 14 patients with severe congestive heart failure (CHF)." | 3.68 | Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides. ( Galvao, M; Jondeau, G; Katz, SD; Klapholz, M; LeJemtel, TH; Levato, P; Maher, M, 1992) |
| "The use of amrinone, a cardiac inotropic agent with vasodilatory properties, has not been described in human pregnancy." | 3.68 | Use of intravenous amrinone in the short-term management of refractory heart failure in pregnancy. ( Bhatia, RK; Ganguly, S; Jelsema, RD, 1991) |
| "The hemodynamic response to amrinone was analyzed in 19 patients with severe heart failure (NYHA III or IV)." | 3.68 | [The hemodynamic profile of the response to amrinone treatment in severe heart failure]. ( Altimiras Ruiz, J; Bayés de Luna, A; Binia Mizrahi, M; Domínguez de Rozas, J; García Picart, J; Guindo Soldevila, J; Pastor Ramón, E, 1991) |
| "The incidence of amrinone-induced thrombocytopenia has been reported to be 2." | 3.68 | Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone. ( Burnette, PK; Manny, RP; Mattingly, PM; Weston, MW, 1990) |
| "To determine the effects of vasodilator and inotropic therapy on hyponatremia in patients with severe heart failure, we measured serum sodium concentration before and after treatment with captopril (70 patients), hydralazine (42 patients), prazosin (22 patients), and amrinone (19 patients), while diuretic dosages were kept constant." | 3.67 | Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Short-term amrinone therapy has been shown to exert beneficial hemodynamic effects in patients with heart failure." | 3.67 | Amrinone therapy in patients with heart failure. Lack of improvement in functional capacity and left ventricular function at rest and during exercise. ( Humen, DP; Johnston, DL; Kostuk, WJ, 1984) |
| "To determine the hemodynamic and clinical effects of long-term positive inotropic stimulation on the myocardium, we treated 31 patients with severe chronic heart failure with oral amrinone (600 mg daily) and performed invasive hemodynamic studies during short- and long-term treatment with the drug." | 3.67 | Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Although amrinone produces acute hemodynamic improvement in patients with severe chronic congestive heart failure (CHF), it has not produced clinical benefits in long-term controlled trials." | 3.67 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Amrinone is a positive inotropic agent which has been widely used for treatment of left heart failure." | 3.67 | [Right ventricular hemodynamics and lung function following amrinone injection]. ( Baur, X; Fruhmann, G; Hauser, F; Klepzig, M; Mernitz, G; Strauer, BE, 1984) |
| "The efficacy of orally active 3, 4-dihydro-6-[4-(3,4- dimethoxybenzoyl )-1-piperazinyl]-2(1H)- quin olinone ( OPC -8212) as a positive inotropic agent was examined using model right-sided heart failure dogs and compared with those of dobutamine and amrinone." | 3.67 | Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure. ( Hashimoto, K; Mori, T; Yabuuchi, Y; Yamashita, S, 1984) |
| "Seven patients with severe congestive heart failure received amrinone i." | 3.67 | Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. ( Hermiller, JB; Leier, CV; Leithe, ME; Magorien, RD; Unverferth, DV, 1984) |
| "The efficacy and safety of oral amrinone were examined in 17 patients with moderately severe to severe heart failure that was refractory to standard medical therapy and vasodilators." | 3.67 | Amrinone in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Sutton, MS; Weber, KT; Wilson, H, 1984) |
| "The frequency and characteristics of thrombocytopenia resulting from administration of amrinone, a new inotropic and vasodilator agent, was evaluated in 43 patients." | 3.67 | Amrinone-induced thrombocytopenia. ( Ansell, J; Benotti, JR; McCue, J; Parrilla, N; Tiarks, C, 1984) |
| "In a prospective trial, the immediate and long-term haematological effects of amrinone were studied in sixteen patients with refractory cardiac failure." | 3.67 | The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. ( Al-Hasani, SF; Hamblin, AS; Kioy, PG; Lucas, GF; Savidge, GF; Semple, MJ; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "The effects of intravenous amrinone and sodium nitroprusside on haemodynamic indices, left ventricular contractility, and myocardial metabolism were compared in patients with cardiac failure." | 3.67 | Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. ( Coltart, DJ; Jenkins, BS; Juul, SM; Thompson, DS; Webb-Peploe, MM; Wilmshurst, PT, 1984) |
| "11 infants and children with severe congestive heart failure after cardiac surgery were treated with Amrinone." | 3.67 | [Effects of amrinone in myocardial insufficiency following heart surgery in children]. ( Seiffert, P; Wessel, A, 1989) |
| "Ten patients with severe chronic heart failure (class III and IV of the NYHA classification) received treatment for severe heart failure with dobutamine (10, then 15 micrograms." | 3.67 | [Severe cardiac decompensation: value in the early hours of a combination of amrinone and dobutamine]. ( Aïtkaciali, F; Cupa, M; Fosse, JP; Fournier, JL; Hoang, P; Pourriat, JL, 1989) |
| "The purpose of this study was to evaluate the effect of amrinone on the survival of a group of 51 Class IV congestive heart failure patients as well as changes in exercise capacity, hemodynamics, and clinical status." | 3.67 | Long term survival of class IV heart failure patients treated with oral amrinone. ( Moran, JF; Rad, N; Scanlon, PJ, 1989) |
| "The relative contribution of inotropic and vasodilator effect to amrinone-induced hemodynamic improvement in congestive heart failure (CHF) is unknown." | 3.67 | Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. ( Cohen, SR; Das, D; Isner, JM; Konstam, MA; Martin, TT; Salem, DN; Weiland, DS, 1986) |
| "Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption." | 3.67 | Effects of amrinone on myocardial energetics in severe congestive heart failure. ( Baim, DS, 1985) |
| "The hemodynamic and hormonal responses to dobutamine alone and with the addition of amrinone were studied in ten patients with severe heart failure." | 3.67 | Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy. ( Kolesar, JA; Lawless, CE; Reddy, PS; Uretsky, BF; Valdes, AM; Verbalis, JG, 1987) |
| "To compare the responses to oral inotropic and vasodilator drugs, maximally effective doses of amrinone (300 mg over 3 hours) and captopril (25 mg orally) were administered to 21 patients with severe chronic heart failure, who had not received either agent previously." | 3.67 | Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1986) |
| "The pharmacokinetics of amrinone and its relationship to ventricular function were assessed in 15 patients with chronic cardiac failure following the administration of a single 100 mg oral dose." | 3.67 | Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ( Andrews, V; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1987) |
| "The effects of amrinone, dobutamine, and a combination of the two drugs on peak positive left ventricular dP/dt and left ventricular performance were evaluated in 11 patients with chronic congestive heart failure." | 3.67 | Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. ( Gage, J; LeJemtel, TH; Lucido, D; Rutman, H, 1986) |
| "To determine the factors conditioning the variability of positive inotropic response after intravenous acute amrinone administration, 14 patients with chronic cardiac failure were studied by quantitative M-mode and cross-sectional echocardiography." | 3.67 | Variability of positive inotropic response to acute amrinone administration in chronic cardiac failure. ( Cargnelli, G; Dalla-Volta, S; Fasoli, G; Maragno, I; Piovan, D; Scognamiglio, R; Visintin, L, 1986) |
| "The hemodynamic effects of a newly developed inotropic agent, amrinone (AMN) were studied and compared with those of dopamine (DA) and dobutamine (DB) in forty patients with pump failure due to acute myocardial infarction." | 3.67 | Effects of intravenous amrinone on heart failure complicated by acute myocardial infarction: comparative study with dopamine and dobutamine. ( Seino, Y; Takano, T; Tanaka, K, 1986) |
| "The aminopyrine breath test (APBT) was used to study patients with chronic congestive heart failure before and after treatment with two chemically similar inotropic agents, amrinone (AR) and milrinone (MR), to determine their effects on hepatic microsomal function." | 3.67 | The effects of two new inotropic agents on microsomal liver function in patients with congestive heart failure. ( Goldfarb, JP; LeJemtel, TH; Manzione, NC; Maskin, CS; Sternlieb, I, 1986) |
| "Amrinone, a new inotropic agent, was used to treat 24 patients with chronic congestive heart failure who were classified as clinically stable and who were in New York Heart Association's classes II and III." | 3.67 | Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure. ( Gerber, L; Merrill, AJ; Silverman, BD, 1985) |
| "Amrinone, a positive inotropic-vasodilator agent, was administered to anaesthetised dogs in an attempt to reverse heart failure induced by drugs possessing negative inotropic properties." | 3.67 | The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog. ( Alousi, AA; Canter, JM; Fort, DJ, 1985) |
| "Seven patients with severe congestive heart failure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72)." | 3.66 | Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure. ( Forman, R; Frishman, W; LeJemtel, TH; Maskin, C; Ribner, H; Siegel, LA; Sonnenblick, EH; Strom, J; Wexler, J, 1983) |
| "We gave intravenous amrinone to 40 patients in heart failure, and oral amrinone to 18 patients." | 3.66 | Side effects of amrinone therapy. ( Webb-Peploe, MM; Wilsmhurst, PT, 1983) |
| "A patient with severe cardiac failure due to idiopathic congestive cardiomyopathy resistant to conventional therapy, responded to amrinone, a new non-glycosidic non-catecholamine positive inotropic agent." | 3.66 | Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure. ( Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981) |
| "Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks)." | 3.66 | Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. ( Forman, R; Klein, NA; LeJemtel, TH; Maskin, CS; Sonnenblick, EH, 1982) |
| "To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27." | 3.66 | Clinical experience with amrinone in patients with advanced congestive heart failure. ( Ballard, JO; Burks, JM; Carlin, B; Hallahan, WF; Kinney, EL; Zelis, R, 1982) |
| "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure." | 3.66 | Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. ( Frishman, WH; Klein, NA; LeJemtel, TH; Siskind, SJ; Sonnenblick, EH, 1981) |
| "The acute effects of an oral preparation of amrinone, a recently synthesized cardiotonic agent, were assessed noninvasively in nine patients who had advanced heart failure that persisted despite treatment with digitalis, diuretic drugs and afterload-reducing agents." | 3.66 | Oral amrinone in refractory congestive heart failure. ( Benotti, JR; Braunwald, E; Curfman, GD; Grossman, W; Holman, BL; Malacoff, RF; Smith, TW; Wynne, J, 1980) |
| "Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown." | 3.66 | Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. ( Benotti, JR; Braunwald, E; Carabello, BA; Grossman, W, 1980) |
| "Eight patients with congestive heart failure and 10 age- and sex-matched healthy volunteers were studied." | 2.69 | Impaired vasodilatation response to amrinone in the forearm of patients with congestive heart failure: role of endothelium-derived nitric oxide. ( Hirano, Y; Inoue, SI; Ishibashi, Y; Murakami, Y; Nakamura, K; Ohata, S; Sakane, T; Shimada, T; Sugamori, T; Takahashi, N, 2000) |
| " After either oral or parenteral administration of milrinone, plasma levels were dose dependent and the drug had an apparent first-order terminal elimination half-life of approximately 2 hr." | 2.66 | Pharmacokinetics of the bipyridines amrinone and milrinone. ( Benotti, J; Benziger, DP; Chatterjee, K; Cody, R; Edelson, J; Hood, WB; Krebs, C; Luczkowec, C; Schwartz, R; Stroshane, R, 1986) |
| "Amrinone is a new positive inotropic agent available in oral and intravenous preparations." | 2.66 | [Effects of amrinone administered orally and by injection in heart failure]. ( Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 2.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Patients with chronic congestive heart failure (CHF) show down-regulation of the beta 1-adrenergic receptor with a decrease in receptor density and altered responses to catecholamines." | 2.38 | Perioperative experience with amrinone. ( Bailey, JM; Levy, JH, 1992) |
| "Amrinone is a potent alternative which combines positive inotropic and vasodilating properties." | 2.38 | [The treatment of heart insufficiency in coronary heart disease]. ( Bertel, O; Gerber, A, 1991) |
| "For amrinone, inefficacy was revealed through carefully designed, placebo-controlled studies despite initial enthusiasm generated by open uncontrolled trials." | 2.38 | Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. ( Hess, ML; Wood, MA, 1989) |
| " Adverse effects are minimal, with dosage limited predominantly by decreases in filling pressures." | 2.37 | Intravenous use of amrinone for the treatment of the failing heart. ( LeJemtel, T; Mancini, D; Sonnenblick, E, 1985) |
| "Which patients with chronic congestive heart failure who are the most likely to benefit from therapy with the novel inotropic agents, and the therapeutic limitations of these agents are discussed." | 2.37 | The role of novel inotropic agents in the treatment of heart failure. ( Keren, G; LeJemtel, TH; Reis, D; Sonnenblick, EH, 1986) |
| " Vasodilator therapy generally fails to reduce pulmonary vascular resistance selectively during long-term administration and frequently leads to systemic hypotension, exacerbation of the pulmonary hypertensive state, worsening of right ventricular failure, and systemic arterial desaturation." | 2.37 | Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. ( Packer, M, 1985) |
| "When congestive heart failure supervenes, the prognosis is poor." | 2.37 | Central and peripheral components of cardiac failure. ( Factor, S; Le Jemtel, TH; Mancini, DM; Sonnenblick, EH, 1986) |
| "Many studies of congestive heart failure are done without explicit diagnostic criteria." | 2.37 | Diagnostic heterogeneity in clinical trials for congestive heart failure. ( Alderman, MH; Marantz, PR; Tobin, JN, 1988) |
| "Amrinone is a bipyridine derivative with positive inotropic effects and vasodilatory properties." | 2.36 | Amrinone. A preliminary review of its pharmacological properties and therapeutic use. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM; Ward, A, 1983) |
| "A 55-year-old man developed acute respiratory failure, pulmonary hypertension and left heart failure due to acute myocardial infarction." | 1.30 | Concurrent administration of amrinone with nitric oxide most improves PaO2/FiO2 in acute respiratory and cardiac failure. ( Fujimori, M; Hayashi, M; Yamada, T; Yukioka, H, 1999) |
| "Amrinone has potent venous and arterial vasodilating properties that make it a unique drug for treating congestive heart failure in addition to its reported positive inotropic effects." | 1.29 | Amrinone: its effect on vascular resistance and capacitance in human subjects. ( Bailey, JM; Levy, JH, 1994) |
| "The prevalence of congestive heart failure (CHF) and its progressive degenerative course continue to generate pressure for alternative, more effective means of treatment." | 1.28 | Home intermittent amrinone infusions in terminal congestive heart failure. ( Baptista, RJ; Mitrano, FP; Perri-LaFrancesca, J, 1989) |
| "The pathophysiology of the syndrome of congestive heart failure (CHF) includes 2 major components that closely interact." | 1.28 | Effects of phosphodiesterase inhibition on skeletal muscle vasculature. ( LeJemtel, TH; Levitt, B; Scortichini, D; Sonnenblick, EH, 1989) |
| "Significant proarrhythmia is uncommon, but can occur." | 1.28 | Electrophysiology of phosphodiesterase inhibitors. ( Goldstein, RA; Naccarelli, GV, 1989) |
| "Amrinone is an effective inotropic agent, but its electrophysiologic effects in humans have not been previously determined." | 1.27 | Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure. ( Dougherty, AH; Goldstein, RA; Gray, EL; Hanna, JE; Naccarelli, GV, 1984) |
| "Amrinone, a new inotropic drug, was infused at a dosage of 2." | 1.27 | Echocardiographic evaluation of cardiovascular effects of amrinone. ( Benassi, A; Mattioli, G; Modena, MG, 1984) |
| " Catecholamine dosage was held constant during the period of the study." | 1.27 | Effect of amrinone in acute severe cardiac failure. ( Frenking, B; Gülker, H; Heuer, H, 1988) |
| "Amrinone (A) has been administered to 10 patients with low postoperative cardiac output as unique inotropic therapy and to 34 patients in severe cardiogenic shock, despite optimal treatment." | 1.27 | New inotropic-vasodilating drugs in acute and chronic heart failure. ( Goenen, MJ, 1986) |
| "Amrinone is a nonadrenergic, nonglycosidic agent with combined positive inotropic and vasodilator properties." | 1.27 | [Use of amrinone in refractory cardiac insufficiency: clinical and hemodynamic evaluation]. ( Bertoni, T; De Martini, M; Foresti, A; Lotto, A; Massari, FM; Valentini, R, 1986) |
| "Chronic congestive heart failure is a frequently occurring disease associated with an impaired quality of life and significant mortality rate." | 1.27 | Chronic congestive heart failure. Where have we been? Where are we heading? ( Applefeld, MM, 1986) |
| "Dobutamine and amrinone were much better tolerated." | 1.27 | Comparative vasoactive therapy for heart failure. ( Alpert, JS; Benotti, JR; McCue, JE, 1985) |
| "Patients with congestive heart failure (CHF) have a high prevalence of complex ventricular arrhythmias." | 1.27 | Electrophysiologic effects of amrinone. ( Dougherty, AH; Goldstein, RA; Gray, EL; Naccarelli, GV, 1985) |
| "Hemodynamic features of acute cardiac failure include decreases in cardiac output and mixed venous O2 saturation, together with increases in left ventricular filling pressure and systemic resistance." | 1.27 | Pathophysiology of cardiac failure. ( Janicki, JS; Maskin, CS; Weber, KT, 1985) |
| "Amrinone was administered 24 hours postoperatively by bolus injection (2 mg/kg) and by 12-hour infusions (20 micrograms/kg/min)." | 1.27 | Amrinone in the management of low cardiac output after open heart surgery. ( Baele, P; Col, J; Goenen, M; Pedemonte, O, 1985) |
| "Amrinone appears to be a promising agent for the long-term treatment of chronic cardiac failure; the utility of pirbuterol, an oral catecholamine analog, remains to be determined." | 1.26 | Cardiotonic agents in the management of chronic cardiac failure. ( Andrews, V; Janicki, JS; Weber, KT, 1982) |
| "Modern management of congestive heart failure (CHF) employs inotropic drugs, vasodilators, and diuretics." | 1.26 | Problems in assessment of new pharmacologic agents for the heart failure patient. ( Benotti, JR; Braunwald, E; Carabello, BA; Colucci, WS; Grossman, W; Malacoff, R; Rude, RE; Wynne, J, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 148 (77.08) | 18.7374 |
| 1990's | 39 (20.31) | 18.2507 |
| 2000's | 3 (1.56) | 29.6817 |
| 2010's | 2 (1.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sircar, I | 3 |
| Steffen, RP | 1 |
| Bobowski, G | 2 |
| Burke, SE | 1 |
| Newton, RS | 1 |
| Weishaar, RE | 2 |
| Bristol, JA | 3 |
| Evans, DB | 3 |
| Duell, BL | 1 |
| Erhardt, PW | 1 |
| Moos, WH | 1 |
| Endoh, M | 1 |
| Wang, Y | 1 |
| Yuan, J | 1 |
| Qian, Z | 1 |
| Zhang, X | 1 |
| Chen, Y | 1 |
| Hou, X | 1 |
| Zou, J | 1 |
| Tadano, N | 1 |
| Morimoto, S | 1 |
| Yoshimura, A | 1 |
| Miura, M | 1 |
| Yoshioka, K | 1 |
| Sakato, M | 1 |
| Ohtsuki, I | 1 |
| Miwa, Y | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| Komamura, K | 2 |
| Matsuo, H | 1 |
| Sasaki, T | 2 |
| el Allaf, D | 1 |
| D'Orio, V | 1 |
| Carlier, J | 1 |
| Sharpe, DN | 1 |
| Weber, KT | 8 |
| Andrews, V | 6 |
| Kinasewitz, GT | 1 |
| Janicki, JS | 7 |
| Fishman, AP | 2 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| Dawson, JR | 2 |
| Bayliss, J | 2 |
| Norell, MS | 1 |
| Canepa-Anson, R | 2 |
| Kuan, P | 1 |
| Reuben, S | 1 |
| Poole-Wilson, PA | 2 |
| Sutton, GC | 2 |
| Scholz, H | 1 |
| Cocco, G | 2 |
| Strozzi, C | 1 |
| Tasini, MT | 1 |
| Padula, A | 1 |
| Urso, L | 1 |
| Rizzo, A | 1 |
| Alfiero, R | 1 |
| Pouleur, H | 1 |
| Detry, JM | 1 |
| Mancia, G | 1 |
| Sfrisi, C | 1 |
| Ferrari, M | 1 |
| Cargnelli, G | 2 |
| Piovan, D | 2 |
| Bova, S | 1 |
| Padrini, R | 1 |
| Packer, M | 6 |
| Medina, N | 4 |
| Yushak, M | 4 |
| Maskin, CS | 6 |
| Le Jemtel, TH | 2 |
| Sonnenblick, EH | 13 |
| Johnston, DL | 1 |
| Humen, DP | 1 |
| Kostuk, WJ | 1 |
| Jerie, P | 1 |
| Larbig, D | 1 |
| Nasse, H | 1 |
| Ward, A | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Taira, N | 2 |
| Evans, JR | 1 |
| Pacht, K | 1 |
| Huss, P | 2 |
| Unverferth, DV | 3 |
| Bashore, TM | 2 |
| Leier, CV | 5 |
| DiBianco, R | 2 |
| Shabetai, R | 1 |
| Silverman, BD | 2 |
| Benotti, JR | 6 |
| Likoff, MJ | 3 |
| Siegel, LA | 2 |
| LeJemtel, TH | 14 |
| Strom, J | 2 |
| Maskin, C | 1 |
| Forman, R | 5 |
| Frishman, W | 1 |
| Wexler, J | 1 |
| Ribner, H | 1 |
| Naccarelli, GV | 3 |
| Gray, EL | 2 |
| Dougherty, AH | 2 |
| Hanna, JE | 1 |
| Goldstein, RA | 5 |
| Modena, MG | 1 |
| Benassi, A | 1 |
| Mattioli, G | 1 |
| Klepzig, M | 2 |
| Baur, X | 1 |
| Hauser, F | 1 |
| Mernitz, G | 1 |
| Fruhmann, G | 1 |
| Strauer, BE | 2 |
| Hashimoto, K | 1 |
| Yabuuchi, Y | 1 |
| Yamashita, S | 1 |
| Mori, T | 1 |
| Kinney, EL | 2 |
| Ballard, JO | 2 |
| Carlin, B | 2 |
| Zelis, R | 2 |
| Dalpiaz, K | 1 |
| Hermiller, JB | 2 |
| Magorien, RD | 2 |
| Leithe, ME | 1 |
| Sutton, MS | 1 |
| Wilson, H | 2 |
| Rocci, ML | 2 |
| Ansell, J | 1 |
| Tiarks, C | 1 |
| McCue, J | 1 |
| Parrilla, N | 1 |
| Wilmshurst, PT | 4 |
| Al-Hasani, SF | 1 |
| Semple, MJ | 1 |
| Hamblin, AS | 1 |
| Kioy, PG | 1 |
| Lucas, GF | 1 |
| Savidge, GF | 1 |
| Webb-Peploe, MM | 5 |
| Kark, P | 1 |
| Gillmer, DJ | 1 |
| Thompson, DS | 3 |
| Juul, SM | 2 |
| Jenkins, BS | 3 |
| Coltart, DJ | 3 |
| Norell, M | 1 |
| Reuben, SR | 1 |
| Hayward, R | 1 |
| Wilsmhurst, PT | 1 |
| Dunkman, WB | 1 |
| Wilen, MM | 1 |
| Franciosa, JA | 2 |
| Reader, C | 2 |
| Peyregne, EA | 1 |
| Suárez, LD | 3 |
| Robinson, PJ | 1 |
| Lvoff, R | 1 |
| Chong, B | 1 |
| Barrett, PA | 1 |
| Klein, NA | 2 |
| Satoh, K | 1 |
| Maruyama, M | 1 |
| Burks, JM | 1 |
| Hallahan, WF | 1 |
| Wilson, JR | 1 |
| Siskind, SJ | 3 |
| Frishman, WH | 1 |
| Jentzer, JH | 1 |
| Kirk, ES | 1 |
| Rude, RE | 1 |
| Grossman, W | 3 |
| Colucci, WS | 2 |
| Carabello, BA | 2 |
| Wynne, J | 2 |
| Malacoff, R | 1 |
| Braunwald, E | 5 |
| Scheuer, J | 1 |
| Malacoff, RF | 1 |
| Curfman, GD | 1 |
| Holman, BL | 1 |
| Smith, TW | 1 |
| Keung, E | 1 |
| Feinberg, H | 1 |
| Efstathakis, D | 1 |
| Kunimoto, F | 1 |
| Arai, K | 1 |
| Isa, Y | 1 |
| Satoh, Y | 1 |
| Fujita, T | 1 |
| Koyano, T | 1 |
| Nagasawa, S | 1 |
| Ohbayashi, T | 1 |
| Kaneko, T | 1 |
| Buser, PT | 1 |
| Wu, SY | 1 |
| Parmley, WW | 1 |
| Jasmin, G | 1 |
| Wikman-Coffelt, J | 1 |
| Rich, MW | 1 |
| Woods, WL | 1 |
| Davila-Roman, VG | 1 |
| Morello, PJ | 1 |
| Kurz, H | 1 |
| Barbarash, R | 1 |
| Spinner, L | 1 |
| Sperry, J | 1 |
| Beckham, V | 1 |
| Coulter, L | 1 |
| Zerkowski, HR | 1 |
| Günnicker, M | 1 |
| Marggraf, G | 1 |
| Reidemeister, JC | 1 |
| Ohizumi, Y | 1 |
| Cheng, DC | 1 |
| Asokumar, B | 1 |
| Nakagawa, T | 1 |
| Levy, JH | 2 |
| Bailey, JM | 2 |
| Levinoff Roth, SN | 1 |
| Moe, G | 1 |
| Sato, Y | 2 |
| Matsumori, A | 3 |
| Sasayama, S | 3 |
| Marius-Nunez, AL | 1 |
| Heaney, L | 1 |
| Fernandez, RN | 1 |
| Clark, WA | 1 |
| Ranganini, A | 1 |
| Silber, E | 1 |
| Denes, P | 1 |
| Ono, K | 1 |
| Shioi, T | 1 |
| Nose, Y | 1 |
| Takeda, S | 1 |
| Takano, T | 3 |
| Nakanishi, K | 1 |
| Nejima, J | 2 |
| Takayama, M | 1 |
| Kim, C | 1 |
| Ogawa, R | 1 |
| Ohte, N | 1 |
| Cheng, CP | 1 |
| Suzuki, M | 1 |
| Little, WC | 1 |
| Tomimoto, S | 1 |
| Noguchi, T | 2 |
| Baba, T | 2 |
| Ohmori, F | 1 |
| Miyatake, K | 1 |
| Lim, YJ | 1 |
| Mishima, M | 1 |
| McCloskey, WW | 1 |
| De Vecchis, R | 1 |
| Pucciarelli, G | 1 |
| Nocerino, L | 1 |
| Cocozza, M | 1 |
| Setaro, A | 1 |
| Torre, G | 1 |
| Imperatore, F | 1 |
| Kanda, M | 1 |
| Yasuda, S | 1 |
| Goto, Y | 1 |
| Sumida, H | 1 |
| Nonogi, H | 1 |
| Yukioka, H | 1 |
| Hayashi, M | 1 |
| Yamada, T | 1 |
| Fujimori, M | 1 |
| Shimosato, G | 1 |
| Matsuda, T | 1 |
| Shigemi, K | 1 |
| Kinoshita, T | 1 |
| Tanaka, Y | 1 |
| Sakane, T | 1 |
| Ishibashi, Y | 1 |
| Shimada, T | 1 |
| Takahashi, N | 1 |
| Sugamori, T | 1 |
| Hirano, Y | 1 |
| Ohata, S | 1 |
| Inoue, SI | 1 |
| Nakamura, K | 1 |
| Murakami, Y | 1 |
| Keung, EC | 1 |
| Schwartz, WJ | 1 |
| Greenberg, MA | 1 |
| Davis, RS | 1 |
| Ribner, HS | 1 |
| Verma, SP | 2 |
| Silke, B | 2 |
| Reynolds, GW | 1 |
| Richmond, A | 2 |
| Taylor, SH | 2 |
| Stengele, E | 1 |
| Trenk, D | 1 |
| Costa, P | 1 |
| Agrò, C | 1 |
| Gulotta, G | 1 |
| Papa, G | 1 |
| Piazza, F | 1 |
| Ronga, F | 1 |
| Sparacia, B | 1 |
| Sansone, A | 1 |
| Jondeau, G | 1 |
| Klapholz, M | 1 |
| Katz, SD | 1 |
| Maher, M | 1 |
| Galvao, M | 1 |
| Levato, P | 1 |
| Dei Cas, L | 1 |
| Metra, M | 1 |
| Nodari, S | 1 |
| Raddino, R | 1 |
| Visioli, O | 1 |
| Costa, R | 1 |
| De Marino, V | 1 |
| Marino, A | 1 |
| Saborowski, F | 1 |
| Peters, P | 1 |
| Schneider, M | 1 |
| Jäger, D | 1 |
| von Dryander, S | 1 |
| Farag, O | 1 |
| Grosskurth, D | 1 |
| Gude, J | 1 |
| Lemke, B | 1 |
| Machraoui, A | 1 |
| Melz, F | 1 |
| Tunn, S | 1 |
| Barmeyer, J | 1 |
| Jelsema, RD | 1 |
| Bhatia, RK | 1 |
| Ganguly, S | 1 |
| Bertel, O | 1 |
| Gerber, A | 1 |
| Domínguez de Rozas, J | 1 |
| García Picart, J | 1 |
| Guindo Soldevila, J | 1 |
| Altimiras Ruiz, J | 1 |
| Binia Mizrahi, M | 1 |
| Pastor Ramón, E | 1 |
| Bayés de Luna, A | 1 |
| Kuch, J | 1 |
| Mattingly, PM | 1 |
| Burnette, PK | 1 |
| Weston, MW | 1 |
| Manny, RP | 1 |
| Marcus, RH | 1 |
| Raw, K | 1 |
| Patel, J | 1 |
| Mitha, A | 1 |
| Sareli, P | 1 |
| Han, YL | 1 |
| Zhu, SJ | 1 |
| Lu, YM | 1 |
| Burns, P | 1 |
| Ondrejicka, JS | 1 |
| Mancini, D | 1 |
| LeJemtel, T | 1 |
| Sonnenblick, E | 1 |
| Wright, RF | 1 |
| Keren, G | 1 |
| Reis, D | 1 |
| Falotico, R | 1 |
| Haertlein, BJ | 1 |
| Lakas-Weiss, CS | 1 |
| Salata, JJ | 1 |
| Tobia, AJ | 1 |
| Baim, DS | 2 |
| Wood, MA | 1 |
| Hess, ML | 2 |
| Maisel, AS | 1 |
| Wright, CM | 1 |
| Carter, SM | 1 |
| Ziegler, M | 1 |
| Motulsky, HJ | 1 |
| Oruaguluchi, G | 1 |
| Zhi, G | 1 |
| Wessel, A | 1 |
| Seiffert, P | 1 |
| Fosse, JP | 1 |
| Pourriat, JL | 1 |
| Hoang, P | 1 |
| Fournier, JL | 1 |
| Aïtkaciali, F | 1 |
| Cupa, M | 1 |
| Baptista, RJ | 1 |
| Mitrano, FP | 1 |
| Perri-LaFrancesca, J | 1 |
| Moran, JF | 1 |
| Rad, N | 1 |
| Scanlon, PJ | 1 |
| Johnston, GD | 1 |
| Vahanian, A | 1 |
| Le Potier, J | 1 |
| Sergent, J | 1 |
| Michel, PL | 1 |
| Acar, J | 1 |
| Andersson, KE | 1 |
| Dhainaut, JF | 1 |
| Scortichini, D | 1 |
| Levitt, B | 1 |
| Mancini, DM | 2 |
| Factor, S | 1 |
| Uretsky, BF | 2 |
| Colombo, F | 1 |
| Libretti, A | 1 |
| Rutman, HI | 1 |
| Bassett, AL | 2 |
| Gaide, MS | 2 |
| Lodge, NJ | 2 |
| Cameron, JS | 2 |
| Konstam, MA | 2 |
| Cohen, SR | 2 |
| Weiland, DS | 1 |
| Martin, TT | 1 |
| Das, D | 2 |
| Isner, JM | 1 |
| Salem, DN | 2 |
| Tommaso, CL | 1 |
| Ruggie, N | 1 |
| Hastillo, A | 1 |
| Thompson, JA | 1 |
| Messner-Pellenc, P | 1 |
| Puech, P | 1 |
| Niu, XL | 1 |
| Erhardt, L | 1 |
| Moore, J | 1 |
| Bolling, SF | 1 |
| Deeb, GM | 1 |
| Crowley, DC | 1 |
| Badellino, MM | 1 |
| Bove, EL | 1 |
| Hertzeanu, H | 1 |
| Pines, A | 1 |
| Marantz, PR | 1 |
| Alderman, MH | 1 |
| Tobin, JN | 1 |
| Lawless, CE | 1 |
| Verbalis, JG | 1 |
| Valdes, AM | 1 |
| Kolesar, JA | 1 |
| Reddy, PS | 1 |
| Corbalán, R | 1 |
| Martínez, A | 1 |
| Illanes, G | 1 |
| Jalil, J | 1 |
| Chamorro, G | 1 |
| Casanegra, P | 1 |
| Roberts, R | 1 |
| Heuer, H | 1 |
| Frenking, B | 1 |
| Gülker, H | 1 |
| Thormann, J | 1 |
| Kramer, W | 1 |
| Kindler, M | 1 |
| Kremer, P | 1 |
| Schlepper, M | 1 |
| Wilmshurst, P | 4 |
| Martínez Martínez, A | 1 |
| Salvati, A | 1 |
| Edelson, J | 1 |
| Stroshane, R | 1 |
| Benziger, DP | 1 |
| Cody, R | 1 |
| Benotti, J | 1 |
| Hood, WB | 1 |
| Chatterjee, K | 1 |
| Luczkowec, C | 1 |
| Krebs, C | 1 |
| Schwartz, R | 1 |
| Hasegawa, GR | 1 |
| Rettig, G | 1 |
| Sen, S | 1 |
| Fröhlig, G | 1 |
| Schieffer, H | 1 |
| Bette, L | 1 |
| Jiang, J | 1 |
| Fu, YS | 1 |
| Huang, DJ | 1 |
| Walker, PC | 1 |
| Perry, BL | 1 |
| Shankaran, S | 1 |
| Lemke, JV | 1 |
| Gage, J | 1 |
| Rutman, H | 1 |
| Lucido, D | 1 |
| Aronovitz, MJ | 1 |
| Brockway, BA | 1 |
| Scognamiglio, R | 1 |
| Fasoli, G | 1 |
| Visintin, L | 1 |
| Maragno, I | 1 |
| Dalla-Volta, S | 1 |
| Tanaka, K | 2 |
| Shimai, S | 1 |
| Takada, K | 1 |
| Koh, M | 1 |
| Seino, Y | 2 |
| Katoh, T | 1 |
| Munakata, K | 1 |
| Hayakawa, H | 1 |
| Goenen, MJ | 1 |
| Geraets, DR | 1 |
| Massari, FM | 1 |
| De Martini, M | 1 |
| Foresti, A | 1 |
| Valentini, R | 1 |
| Bertoni, T | 1 |
| Lotto, A | 1 |
| Massie, B | 1 |
| Bourassa, M | 1 |
| Hess, M | 1 |
| Konstam, M | 1 |
| Likoff, M | 1 |
| Treadway, G | 1 |
| Bounhoure, JP | 1 |
| Massabuau, P | 1 |
| Puel, J | 1 |
| Miquel, JP | 1 |
| Calazel, J | 1 |
| Guevara, E | 1 |
| Delisio, HJ | 1 |
| Kleinhans, E | 1 |
| Büll, U | 1 |
| Kimura, S | 1 |
| Kozlovskis, PL | 1 |
| Myerburg, RJ | 1 |
| Applefeld, MM | 1 |
| Manzione, NC | 1 |
| Goldfarb, JP | 1 |
| Sternlieb, I | 1 |
| Merrill, AJ | 1 |
| Gerber, L | 1 |
| Dittrich, HC | 1 |
| Walker, JM | 1 |
| McCue, JE | 1 |
| Alpert, JS | 1 |
| Hussain, M | 1 |
| Reynolds, G | 1 |
| Jackson, NC | 1 |
| Hafizullah, M | 1 |
| Goenen, M | 1 |
| Pedemonte, O | 1 |
| Baele, P | 1 |
| Col, J | 1 |
| Alousi, AA | 1 |
| Canter, JM | 1 |
| Fort, DJ | 1 |
| Hoffmann, P | 1 |
| Schockenhoff, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children[NCT02728128] | 53 participants (Actual) | Observational | 2016-08-31 | Completed | |||
| Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study)[NCT02767024] | Phase 4 | 0 participants (Actual) | Interventional | 2018-05-01 | Withdrawn (stopped due to No patients enrolled) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
34 reviews available for amrinone and Cardiac Failure
| Article | Year |
|---|---|
In search of the digitalis replacement.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Fai | 1987 |
The new inotropic phosphodiesterase inhibitors.
Topics: Aminopyridines; Amrinone; Calcium; Carbamates; Cardiotonic Agents; Cardiovascular Agents; Enoximone; | 1984 |
Newer inotropic agents.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Dobutamine; Ethanolamines; Heart Failure; Humans; Prac | 1984 |
Vasodilator and inotropic agents in treatment of chronic cardiac failure: clinical experience and response in exercise performance.
Topics: Aerobiosis; Aminopyridines; Amrinone; Anaerobiosis; Cardiotonic Agents; Heart Failure; Hemodynamics; | 1981 |
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
[Old and new positive inotropic drugs: problems and controversies].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; G | 1984 |
[Positive inotropic therapy of cardiac failure: old and new drugs, controversies and tests].
Topics: Aminopyridines; Amrinone; Cardiac Glycosides; Cardiotonic Agents; Glucagon; Heart Failure; Histamine | 1984 |
[Treatment of refactory heart failure].
Topics: Adult; Aged; Aminopyridines; Amrinone; Captopril; Diet, Sodium-Restricted; Digitalis Glycosides; Diu | 1983 |
Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
Topics: Absorption; Aminopyridines; Amrinone; Animals; Calcium; Cardiotonic Agents; Dogs; Dose-Response Rela | 1983 |
[Amrinone, a new cardiotonic agent].
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cats; Guinea Pigs; Heart Failure; Humans; Myo | 1983 |
[Tendency of development on novel type of cardiotonic drugs].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Amrinone; Animals; Calcium; Catechols | 1993 |
[Apical filling abnormality in patients with heart failure assessed with contrast echocardiography using venous injection of Albunex].
Topics: Albumins; Amrinone; Contrast Media; Echocardiography; Heart Failure; Humans; Injections, Intravenous | 1998 |
Use of intravenous inotropic therapy in the home.
Topics: Amrinone; Cardiotonic Agents; Dobutamine; Heart Failure; Home Infusion Therapy; Humans; Infusions, I | 1998 |
Perioperative experience with amrinone.
Topics: Amrinone; Cardiac Output, Low; Cardiac Surgical Procedures; Heart Failure; Hemodynamics; Humans | 1992 |
[Physiological bases and therapeutic uses of inodilator drugs].
Topics: Amrinone; Cardiotonic Agents; Deoxyepinephrine; Dobutamine; Dopamine; Heart Failure; Humans; Milrino | 1991 |
[The treatment of heart insufficiency in coronary heart disease].
Topics: Amrinone; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Bypass; Coronary Di | 1991 |
Intravenous use of amrinone for the treatment of the failing heart.
Topics: Aminopyridines; Amrinone; Cardiac Complexes, Premature; Cardiac Output; Cardiotonic Agents; Drug Int | 1985 |
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1986 |
The role of novel inotropic agents in the treatment of heart failure.
Topics: Amrinone; Animals; Cardiotonic Agents; Dobutamine; Enoximone; Heart Failure; Hemodynamics; Humans; I | 1986 |
Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
Topics: Administration, Oral; Amrinone; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; Phosphodies | 1989 |
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Blood Pressure; Ca | 1985 |
Effects of new inotropic agents on exercise performance.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Chronic Dise | 1986 |
Some new positive inotropic agents.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; D | 1986 |
Central and peripheral components of cardiac failure.
Topics: Aminopyridines; Amrinone; Animals; Captopril; Cardiac Output; Cardiomegaly; Cardiotonic Agents; Cate | 1986 |
[Rational and irrational approach to the inotropic agent therapy of heart failure].
Topics: Amrinone; Cardiotonic Agents; Digitalis Glycosides; Heart Failure; Humans; Imidazoles; Milrinone; Py | 1988 |
Newer cardiotonic agents: implications for patients with heart failure and ischemic heart disease.
Topics: Amrinone; Cardiotonic Agents; Coronary Disease; Heart Failure; Humans; Phosphodiesterase Inhibitors; | 1987 |
Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Calcium; Cardiac Output; Cardi | 1986 |
Congestive heart failure.
Topics: Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic | 1986 |
[Multicenter study of the hemodynamic action of intravenous amrinone in the treatment of acute congestive cardiac failure].
Topics: Acute Disease; Adult; Aged; Amrinone; France; Heart Failure; Hemodynamics; Humans; Middle Aged; Mult | 1988 |
[New inotropic agents in the treatment of refractory congestive heart failure].
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Pyridones | 1988 |
Diagnostic heterogeneity in clinical trials for congestive heart failure.
Topics: Amrinone; Clinical Trials as Topic; Digoxin; Heart Failure; Humans; Hydralazine; Metoprolol; Researc | 1988 |
Inotropic support in patients with left ventricular dysfunction.
Topics: Acute Disease; Amrinone; Catecholamines; Digitalis Glycosides; Heart Failure; Humans | 1987 |
Clinical effects of intravenous amrinone in patients with congestive heart failure.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Electrophysiology; Heart Failure; Hemodynamics; Humans | 1986 |
Milrinone, a new agent for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Milrinon | 1986 |
24 trials available for amrinone and Cardiac Failure
| Article | Year |
|---|---|
Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as | 1984 |
Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic | 1984 |
Intravenous amrinone for congestive heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; Heart | 1984 |
Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy.
Topics: Aminopyridines; Amrinone; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Female; Heart Failure; H | 1983 |
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Drug Therapy, Combinatio | 1983 |
[Hemodynamic effects of amrinone on patients with moderate and severe cardiac dysfunction after open heart surgery].
Topics: Adult; Aged; Amrinone; Cardiac Surgical Procedures; Catecholamines; Female; Heart Failure; Hemodynam | 1995 |
A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure.
Topics: Aged; Aged, 80 and over; Amrinone; Analysis of Variance; Dobutamine; Double-Blind Method; Female; He | 1995 |
[Concept for therapy of heart failure in heart surgery].
Topics: Amrinone; Cardiac Output, Low; Enoximone; Heart Diseases; Heart Failure; Heart Rate; Heart Transplan | 1994 |
Amrinone improves lung compliance in patients receiving mechanical ventilation for cardiogenic pulmonary edema.
Topics: Aged; Amrinone; Blood Gas Analysis; Cyclic AMP; Cyclic GMP; Female; Heart Failure; Hemodynamics; Hum | 1997 |
Impaired vasodilatation response to amrinone in the forearm of patients with congestive heart failure: role of endothelium-derived nitric oxide.
Topics: Acetylcholine; Aged; Amrinone; Endothelium, Vascular; Enzyme Inhibitors; Female; Forearm; Heart Fail | 2000 |
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate.
Topics: Adult; Aged; Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Heart Failure; Humans; Isosorbide Di | 1992 |
[Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure].
Topics: Adult; Aged; Aged, 80 and over; Amrinone; Dose-Response Relationship, Drug; Drug Tolerance; Female; | 1991 |
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure].
Topics: Aged; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; | 1991 |
Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy.
Topics: Adult; Amrinone; Cardiomyopathy, Dilated; Dobutamine; Female; Heart Failure; Hemodynamics; Humans; I | 1990 |
[Multicenter study of the hemodynamic action of intravenous amrinone in the treatment of acute congestive cardiac failure].
Topics: Acute Disease; Adult; Aged; Amrinone; France; Heart Failure; Hemodynamics; Humans; Middle Aged; Mult | 1988 |
[Clinical effects of the infusion of dobutamine and amrinone in patients with refractory cardiac insufficiency].
Topics: Aged; Aged, 80 and over; Amrinone; Body Weight; Clinical Trials as Topic; Dobutamine; Female; Heart | 1987 |
Pharmacokinetics of the bipyridines amrinone and milrinone.
Topics: Administration, Oral; Aminopyridines; Amrinone; Clinical Trials as Topic; Half-Life; Heart Failure; | 1986 |
Withdrawal of long-term amrinone therapy in patients with congestive heart failure: a placebo controlled trial.
Topics: Adult; Aged; Amrinone; Clinical Trials as Topic; Double-Blind Method; Female; Heart Failure; Humans; | 1986 |
[A preliminary study on the effect of oral amrinone in refractory congestive heart failure].
Topics: Administration, Oral; Adult; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; Female; Heart F | 1986 |
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; Double | 1985 |
Clinical safety of intravenous amrinone--a review.
Topics: Aminopyridines; Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Clinical Trials as Topic; Drug I | 1985 |
[Effects of amrinone administered orally and by injection in heart failure].
Topics: Administration, Oral; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Clinical Trials as Topic; | 1985 |
[Amrinone in the treatment of severe cardiac insufficiency].
Topics: Adult; Aged; Amrinone; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; M | 1985 |
Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dose-Resp | 1985 |
135 other studies available for amrinone and Cardiac Failure
| Article | Year |
|---|---|
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cardiotonic Agents; Dogs; Female; Fibrinolytic Agents; | 1989 |
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
Topics: Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Chemical Phenomena; Chemistry, Physical; D | 1985 |
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
Topics: Animals; Cardiotonic Agents; Dogs; Guinea Pigs; Heart Failure; Myocardial Contraction; Phosphodieste | 1984 |
Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy.
Topics: Amrinone; Animals; Calcium Signaling; Cardiotonic Agents; Chronic Disease; Disease Models, Animal; D | 2013 |
β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Amrinone; Animals; Arrhythmias, Ca | 2015 |
SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure.
Topics: Amrinone; Animals; Calcium; Cardiotonic Agents; Dihydropyridines; Disease Models, Animal; Dogs; Hear | 2005 |
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.
Topics: Aged; Amrinone; Cardiotonic Agents; Chi-Square Distribution; Cost-Benefit Analysis; Dobutamine; Drug | 2008 |
Clinical studies with beta 2 adrenoceptor agonists in heart failure.
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Ethanolamines; He | 1982 |
Inotropic drugs in the treatment of heart failure.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Glycosides; Cardiotonic Agents; Cyclic A | 1984 |
Inotropic drugs of the future.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Imidazoles; Practolol; Prenalte | 1982 |
[New inotropic drugs].
Topics: Aminopyridines; Amrinone; Calcium; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Drug Evalua | 1982 |
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition.
Topics: Adult; Aged; Aminopyridines; Amrinone; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardioto | 1984 |
Inotropic drugs for treatment of the failing heart.
Topics: Aminophylline; Aminopyridines; Amrinone; Cardiotonic Agents; Catecholamines; Digitalis Glycosides; G | 1984 |
Amrinone therapy in patients with heart failure. Lack of improvement in functional capacity and left ventricular function at rest and during exercise.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cerebral Ventriculograp | 1984 |
[Alternatives to digitalis therapy].
Topics: Aminopyridines; Amrinone; Captopril; Catecholamines; Diuretics; Heart Failure; Humans; Hydralazine; | 1983 |
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Chronic Disease; Female; Heart Failure; Human | 1984 |
Amrinone: a promising new cardiotonic agent in the treatment of chronic cardiac failure.
Topics: Activities of Daily Living; Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cats; Chronic Dis | 1983 |
Improvement in exercise capacity despite cardiac deteriora tion: nonivasive assessment of long-term therapy with amrinone in severe heart failure.
Topics: Adult; Aminopyridines; Amrinone; Cardiotonic Agents; Exercise Test; Female; Follow-Up Studies; Heart | 1983 |
Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure.
Topics: Adult; Aminopyridines; Amrinone; Atrioventricular Node; Cardiotonic Agents; Electrocardiography; Fem | 1984 |
Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiotonic Agents; Chronic Disease; Dose-Res | 1984 |
Echocardiographic evaluation of cardiovascular effects of amrinone.
Topics: Adult; Aminopyridines; Amrinone; Cardiac Catheterization; Cardiomyopathy, Dilated; Cardiotonic Agent | 1984 |
[Right ventricular hemodynamics and lung function following amrinone injection].
Topics: Airway Resistance; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Heart Ventricles; He | 1984 |
Positive inotropic effect of 3, 4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-qu inolinone (OPC-8212) in the dog with experimentally-induced right-sided heart failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiotonic Agents; Dobutam | 1984 |
Amrinone-mediated thrombocytopenia.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Platelet Count; Thrombocytopeni | 1983 |
Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dobutamin | 1984 |
Amrinone in the treatment of chronic cardiac failure.
Topics: Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evalu | 1984 |
Amrinone-induced thrombocytopenia.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Platelets; Dose-Response Relationship, Drug; Female; He | 1984 |
The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Platelets; Cardiotonic Agents; Cell Survival; Female; H | 1984 |
Dangers of amrinone.
Topics: Aminopyridines; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Heart Failure; Humans | 1984 |
Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy.
Topics: Adult; Aminopyridines; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Disease; Fema | 1984 |
Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function.
Topics: Adult; Aminopyridines; Amrinone; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heart | 1983 |
Amrinone--promising innovation for treatment of the failing heart.
Topics: Aminopyridines; Amrinone; Heart Failure; Humans; Kinetics; Myocardial Contraction; Stimulation, Chem | 1983 |
Side effects of amrinone therapy.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Female; Heart Failu | 1983 |
Adverse effects of long-term amrinone administration in congestive heart failure.
Topics: Abdomen; Aged; Aminopyridines; Amrinone; Cough; Heart Failure; Humans; Liver Function Tests; Male; M | 1983 |
Amrinone therapy in congestive cardiomyopathy.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Female; Heart Failure; Humans; Middle Aged | 1983 |
Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Hemodynamics; Hum | 1981 |
Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease.
Topics: Administration, Oral; Adult; Aminopyridines; Amrinone; Cardiotonic Agents; Female; Heart Failure; He | 1982 |
Cardiotonic agents in the management of chronic cardiac failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dobutamin | 1982 |
The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog.
Topics: Aminopyridines; Amrinone; Animals; Cardiac Output; Cardiotonic Agents; Dogs; Heart Failure; Heart Ra | 1982 |
Clinical experience with amrinone in patients with advanced congestive heart failure.
Topics: Administration, Oral; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Inf | 1982 |
Amrinone and exercise performance in patients with chronic heart failure.
Topics: Aminopyridines; Amrinone; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Human | 1981 |
Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Catecholamines; Chronic Disease; | 1981 |
Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs.
Topics: Acute Disease; Aminopyridines; Amrinone; Animals; Blood Circulation; Coronary Circulation; Dogs; Fem | 1981 |
Problems in assessment of new pharmacologic agents for the heart failure patient.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Cardiovascular Agents; Drug Evaluation; Energy Metabol | 1981 |
Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure.
Topics: Adolescent; Adult; Aminopyridines; Amrinone; Blood Pressure; Exercise Test; Female; Heart Failure; H | 1981 |
Oral amrinone in refractory congestive heart failure.
Topics: Aged; Aminopyridines; Amrinone; Blood Pressure; Coronary Disease; Electrocardiography; Female; Heart | 1980 |
Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.
Topics: Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disea | 1980 |
Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Drug Ther | 1981 |
Distinct modulation of myocardial performance, energy metabolism, and [Ca2+]i transients by positive inotropic drugs in normal and severely failing hamster hearts.
Topics: Amrinone; Animals; Blood Pressure; Bucladesine; Calcium; Cardiomyopathies; Cardiotonic Agents; Crice | 1995 |
Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery.
Topics: Adult; Amrinone; Aortic Valve; Cardiopulmonary Bypass; Drug Therapy, Combination; Female; Heart Fail | 1993 |
Amrinone: its effect on vascular resistance and capacitance in human subjects.
Topics: Amrinone; Arteries; Blood Circulation; Blood Pressure; Blood Volume; Cardiopulmonary Bypass; Heart F | 1994 |
Intermittent intravenous amrinone infusion: a potentially cost effective mode of treatment of patients with refractory heart failure.
Topics: Aged; Aged, 80 and over; Amrinone; Female; Heart Failure; Hospitalization; Humans; Infusions, Intrav | 1993 |
Inotropic agent vesnarinone inhibits cytokine production and E-selectin expression in human umbilical vein endothelial cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cardiotonic Agents; Cell Adhesion; Cells, Cultured | 1995 |
Role of cytokines in the syndrome of heart failure.
Topics: Adrenergic beta-Agonists; Amrinone; Animals; Cardiotonic Agents; Cytokines; Heart Failure; Humans; K | 1996 |
Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure.
Topics: Ambulatory Care; Amrinone; Cardiotonic Agents; Cost-Benefit Analysis; Dobutamine; Drug Administratio | 1996 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzy | 1996 |
The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure.
Topics: Amrinone; Animals; Dogs; Heart Failure; Phosphodiesterase Inhibitors; Physical Conditioning, Animal; | 1997 |
Hemodynamic effect of amrinone depends on pretreatment vascular resistance in patients with evolving congestive heart failure: correlation between vascular resistance and neurohormonal activity.
Topics: Aged; Amrinone; Angiotensin II; Biomarkers; Cardiotonic Agents; Endothelin-1; Female; Heart Failure; | 1998 |
[The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
Topics: Aged; Amrinone; Cardiotonic Agents; Diuresis; Dobutamine; Dopamine; Drug Evaluation; Drug Therapy, C | 1998 |
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Topics: Aged; Aged, 80 and over; Amrinone; Creatinine; Diuresis; Female; Follow-Up Studies; Heart Failure; H | 1999 |
Severe heart failure: balancing length and quality of life.
Topics: Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milrinone; Phosphodiesterase Inhibitors; Pyrazi | 1999 |
Concurrent administration of amrinone with nitric oxide most improves PaO2/FiO2 in acute respiratory and cardiac failure.
Topics: Acute Disease; Amrinone; Cardiotonic Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; | 1999 |
[General anesthesia for a patient with primary aldosteronism complicated with hypertrophic nonobstructive cardiomyopathy].
Topics: Adrenal Glands; Adult; Amrinone; Anesthesia, General; Cardiomyopathy, Hypertrophic; Heart Failure; H | 1999 |
Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration.
Topics: Administration, Oral; Aminopyridines; Amrinone; Dose-Response Relationship, Drug; Female; Heart Fail | 1979 |
[Use of amrinone in terminal dialysis-dependent renal failure].
Topics: Aged; Amrinone; Electrocardiography; Heart Failure; Hemodynamics; Humans; Kidney Failure, Chronic; M | 1992 |
[Efficacy and safety of amrinone in the treatment of heart insufficiency in intensive care].
Topics: Acute Disease; Aged; Aged, 80 and over; Amrinone; Chronic Disease; Critical Care; Female; Heart Fail | 1992 |
Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides.
Topics: Aged; Aged, 80 and over; Amrinone; Arterioles; Blood Flow Velocity; Digitalis Glycosides; Digoxin; F | 1992 |
[Catecholamine regulation and ANP changes after hemodynamic improvement of dysfunctional and insufficient hearts by phosphodiesterase III inhibitors].
Topics: Amrinone; Atrial Natriuretic Factor; Epinephrine; Heart Failure; Hemodynamics; Humans; Middle Aged; | 1991 |
Use of intravenous amrinone in the short-term management of refractory heart failure in pregnancy.
Topics: Acidosis, Lactic; Adult; Amrinone; Arrhythmias, Cardiac; Endocarditis, Bacterial; Female; Heart Fail | 1991 |
[The hemodynamic profile of the response to amrinone treatment in severe heart failure].
Topics: Amrinone; Cardiomyopathy, Dilated; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Inf | 1991 |
[Wincoram (amrinone) in severe congestive heart failure].
Topics: Amrinone; Heart Failure; Humans | 1990 |
Pancytopenia secondary to short-term, high-dose intravenous infusion of amrinone.
Topics: Amrinone; Bone Marrow; Dopamine; Heart Failure; Humans; Hypotension; Infusions, Intravenous; Male; M | 1990 |
[Clinical effect of China-made amrinone in the treatment of refractory congestive heart failure].
Topics: Adult; Amrinone; Digitalis; Electrocardiography, Ambulatory; Female; Heart Failure; Hemodynamics; Hu | 1990 |
Criteria for use of amrinone lactate in hospitalized adult patients.
Topics: Acute Disease; Adult; Amrinone; Clinical Protocols; Heart Failure; Hospitalization; Humans; Middle A | 1990 |
Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Topics: Amrinone; Anesthesia; Animals; Ferrets; Heart Failure; Heart Rate; Hemodynamics; In Vitro Techniques | 1989 |
Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.
Topics: Amrinone; Animals; Coronary Circulation; Enoximone; Heart Failure; Humans; Imidazoles; Milrinone; My | 1989 |
Tachyphylaxis with amrinone therapy: association with sequestration and down-regulation of lymphocyte beta-adrenergic receptors.
Topics: Aged; Amrinone; Cardiac Output; Cyclic AMP; Drug Tolerance; Female; Heart Failure; Humans; Infusions | 1989 |
13th Alexander Brown memorial lecture given on 22 February 1985 by G. Onuaguluchi. "Cardiotonic Drugs in the Management of Chronic Congestive Heart Failure: Digitalis Revisited ".
Topics: Amrinone; Animals; Digitalis Glycosides; Guinea Pigs; Heart Failure; Hemodynamics; Humans; Rabbits | 1989 |
[Hemodynamic changes caused by a single intravenous dose of amrinone in congestive heart failure].
Topics: Adult; Amrinone; Cardiac Output; Cyclic AMP; Female; Heart Failure; Hemodynamics; Humans; Male; Midd | 1989 |
[Effects of amrinone in myocardial insufficiency following heart surgery in children].
Topics: Adolescent; Amrinone; Blood Pressure; Cardiac Output; Child; Child, Preschool; Echocardiography; Fem | 1989 |
[Severe cardiac decompensation: value in the early hours of a combination of amrinone and dobutamine].
Topics: Aged; Aged, 80 and over; Amrinone; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; Hem | 1989 |
Home intermittent amrinone infusions in terminal congestive heart failure.
Topics: Aged; Amrinone; Drug Administration Schedule; Heart Failure; Home Nursing; Humans; Infusions, Intrav | 1989 |
Long term survival of class IV heart failure patients treated with oral amrinone.
Topics: Aged; Amrinone; Angiocardiography; Echocardiography; Electrocardiography; Exercise Test; Female; Hea | 1989 |
Alternatives to the digitalis glycosides for heart failure.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Milri | 1985 |
[Positive inotropic agents. Generalities and classification].
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Calcium; Cardiotonic Agents; Digitalis Glycoside | 1985 |
[Use of new inotropic agents in the treatment of acute cardiac failure].
Topics: Adrenergic Agonists; Amrinone; Calcium Channel Blockers; Cardiotonic Agents; Dobutamine; Dopamine; E | 1988 |
Effects of phosphodiesterase inhibition on skeletal muscle vasculature.
Topics: Amrinone; Animals; Heart Failure; Humans; Milrinone; Muscles; Phosphodiesterase Inhibitors; Physical | 1989 |
Electrophysiology of phosphodiesterase inhibitors.
Topics: Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Electrocardiography; Electrophysiology; Heart Co | 1989 |
Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
Topics: Amrinone; Cardiotonic Agents; Digoxin; Dobutamine; Enoximone; Ethanolamines; Heart; Heart Failure; H | 1986 |
General overview and update of positive inotropic therapy.
Topics: Amrinone; Blood Pressure; Cardiotonic Agents; Digitoxin; Dobutamine; Dopamine; Enoximone; Heart Fail | 1986 |
New positive inotropic drugs for the treatment of congestive heart failure.
Topics: Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Dipeptides; Dobutamine; Enalapril; Hea | 1985 |
Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Cats; Cyclic | 1985 |
Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Female; Heart; Heart Fail | 1986 |
Advances in the diagnosis and management of congestive heart failure.
Topics: Amrinone; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output; Digitalis Glycosides; Diuretics; | 1987 |
Effects of amrinone on myocardial energetics in severe congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Coronary Circulation; Dogs; Enoximone; Heart; | 1985 |
[Hemodynamic effect of domestic amrinone in patients with congestive heart failure and pulmonary hypertension].
Topics: Adolescent; Adult; Aged; Amrinone; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmon | 1988 |
[Phosphodiesterase inhibitors--a new therapeutic principle in heart failure].
Topics: Amrinone; Heart Failure; Humans; Phosphodiesterase Inhibitors | 1988 |
Intravenous amrinone therapy at home for the patient with chronic congestive heart failure.
Topics: Aged; Amrinone; Heart Failure; Home Care Services; Home Nursing; Humans; Infusions, Intravenous; Mal | 1988 |
Prolonged amrinone therapy prior to orthotopic cardiac transplantation in patients with pulmonary hypertension.
Topics: Adolescent; Adult; Amrinone; Child; Drug Evaluation; Female; Heart Diseases; Heart Failure; Heart Tr | 1988 |
Combined therapy with dobutamine and amrinone in severe heart failure. Improved hemodynamics and increased activation of the renin-angiotensin system with combined intravenous therapy.
Topics: Adult; Amrinone; Arginine Vasopressin; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; | 1987 |
Inotropic therapy for cardiac failure associated with acute myocardial infarction.
Topics: Amrinone; Cardiotonic Agents; Digoxin; Diuretics; Dobutamine; Dopamine; Heart Failure; Humans; Myoca | 1988 |
Effect of amrinone in acute severe cardiac failure.
Topics: Acute Disease; Adult; Amrinone; Blood Pressure; Female; Heart Failure; Heart Rate; Humans; Male; Mid | 1988 |
[Determination of active components of amrinone by analysis of pressure-volume results; use of the conductance (volume) catheter technic and rapid load change by balloon occlusion of the inferior vena cava].
Topics: Amrinone; Cardiac Catheterization; Cardiac Output, Low; Cardiomyopathy, Dilated; Dobutamine; Drug Th | 1987 |
Beneficial effects of amrinone in patients with heart failure.
Topics: Amrinone; Animals; Heart Failure; Humans; Myocardial Contraction | 1987 |
[Combination of different inotropic agents in the treatment of chronic refractory cardiac insufficiency].
Topics: Amrinone; Dobutamine; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Male; | 1987 |
Comparative immediate hemodynamic and hormonal effects of amrinone and captopril in patients with severe chronic heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Captopril; Cardiac Output; Cardiotonic Agents | 1986 |
Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology.
Topics: Acetylation; Amrinone; Cardiac Output; Chronic Disease; Half-Life; Heart Failure; Hemodynamics; Huma | 1987 |
Effects of amrinone.
Topics: Amrinone; Ferricyanides; Heart Failure; Hemodynamics; Humans; Nitroprusside | 1987 |
Safety of amrinone for treating congestive heart failure in a premature neonate.
Topics: Amrinone; Heart Failure; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 1987 |
New inotropic drugs: amrinone and milrinone.
Topics: Amrinone; Heart Failure; Humans; Milrinone; Pyridones | 1987 |
Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Dobutamine; Drug Synergism; Female; Heart Fai | 1986 |
Effect of amrinone on right ventricular function: predominance of afterload reduction.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Female; Heart Failure; Hemodynamics; Humans; | 1986 |
New positive inotropic agents for congestive heart failure.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Drug Evaluation; Heart Failure; Humans; Milri | 1986 |
Variability of positive inotropic response to acute amrinone administration in chronic cardiac failure.
Topics: Adult; Amrinone; Echocardiography; Heart Failure; Humans; Infusions, Parenteral; Middle Aged; Myocar | 1986 |
[Effects of intravenous amrinone (Win 40680) on heart failure complicated by acute myocardial infarction: comparative study with dopamine and dobutamine].
Topics: Aged; Amrinone; Dobutamine; Dopamine; Female; Heart Failure; Humans; Injections, Intravenous; Male; | 1986 |
New inotropic-vasodilating drugs in acute and chronic heart failure.
Topics: Acute Disease; Administration, Oral; Amrinone; Cardiotonic Agents; Chronic Disease; Heart Failure; H | 1986 |
Effects of intravenous amrinone on heart failure complicated by acute myocardial infarction: comparative study with dopamine and dobutamine.
Topics: Aged; Amrinone; Dobutamine; Dopamine; Female; Heart Failure; Hemodynamics; Humans; Injections, Intra | 1986 |
Drug therapy for congestive heart failure.
Topics: Amrinone; Dobutamine; Heart Failure; Humans | 1986 |
[Use of amrinone in refractory cardiac insufficiency: clinical and hemodynamic evaluation].
Topics: Administration, Oral; Adult; Aged; Amrinone; Female; Heart Failure; Hemodynamics; Humans; Injections | 1986 |
Vasodilator effect of amrinone in the pulmonary and systemic circulation.
Topics: Amrinone; Heart Failure; Humans; Myocardial Contraction; Pulmonary Circulation; Vasodilation | 1986 |
[Amrinone in acute and long-term therapy].
Topics: Administration, Oral; Aminopyridines; Amrinone; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronar | 1985 |
Alternative to the digitalis glycosides for heart failure.
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Digitalis Glycosides; Heart Failure; Humans | 1985 |
Effects of amrinone on contraction and K+-induced contracture of normal and subacutely failed cat ventricular muscle.
Topics: Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cats; Dogs; Dose-Response Relationship, Drug; | 1986 |
Chronic congestive heart failure. Where have we been? Where are we heading?
Topics: Aminopyridines; Amrinone; Biopsy; Calcium Channel Blockers; Cardiology; Chronic Disease; Digitalis; | 1986 |
The effects of two new inotropic agents on microsomal liver function in patients with congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Aminopyrine; Amrinone; Breath Tests; Cardiac Output; Cardiotonic Agents | 1986 |
Intravenous amrinone: an advance or a wrong step?
Topics: Aminopyridines; Amrinone; Cardiotonic Agents; Heart Failure; Humans; Infusions, Parenteral; Vasodila | 1985 |
Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Chronic Disease; El | 1985 |
Effects of intracoronary and intravenous amrinone infusions in patients with cardiac failure and patients with near normal cardiac function.
Topics: Adult; Aminopyridines; Amrinone; Angina Pectoris; Blood Pressure; Cardiomyopathy, Dilated; Cardioton | 1985 |
A symposium: Amrinone. Introduction.
Topics: Aminopyridines; Amrinone; Diuretics; Heart Failure; Humans; Vasodilator Agents | 1985 |
Comparative vasoactive therapy for heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Blood Pressure; Cardiac Output; Cardiot | 1985 |
Electrophysiologic effects of amrinone.
Topics: Adult; Aged; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Cardiac Output; Cardiac Pacing, Artific | 1985 |
Pathophysiology of cardiac failure.
Topics: Aminopyridines; Amrinone; Blood Pressure; Cardiac Output; Cardiotonic Agents; Dobutamine; Dopamine; | 1985 |
Amrinone in the management of low cardiac output after open heart surgery.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Cardiac Output, Low; Cardiac Surgical Procedu | 1985 |
The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog.
Topics: Aminopyridines; Amrinone; Animals; Blood Pressure; Cardiac Output; Cardiotonic Agents; Central Venou | 1985 |
[Amrinone in catecholamine refractory heart failure in septic shock].
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Catecholamines; Dose-Response Relationshi | 1985 |